Although NY-ESO-1 and MAGEA3 are currently undergoing clinical trials in various human malignancies, including NSCLC, the use of single antigen vaccine formulations have often been met with limited clinical outcomes [14], [15], [16], [30]. Here, MAGEA3 is linked to non-small cell lung carcinoma.